Last update at 2025-07-01T16:54:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
BioSig Stock Surges Following Share Exchange Deal With Streamex
Mon 26 May 25, 04:42 PMIs Adaptive Biotechnologies (ADPT) Outperforming Other Medical Stocks This Year?
Mon 26 May 25, 01:40 PMPacBio Stock Slips Despite New China Distribution Deal With Haorui
Fri 23 May 25, 02:46 PMReasons to Retain TransMedics Stock in Your Portfolio for Now
Fri 23 May 25, 02:36 PMCMS to recover ‘uncollected overpayments’ amid Medicare audits
Thu 22 May 25, 08:55 PMJP Morgan Keeps Faith in UnitedHealth (UNH) Amid Regulatory Reviews
Thu 22 May 25, 08:43 PMAMIX Stock May Climb Following Key U.S. Patent for Nerve-Sensing Tech
Thu 22 May 25, 03:39 PMMedicare audits, Advance Auto Parts, solar: Trending Tickers
Thu 22 May 25, 02:37 PMBAX Stock May Rise Following the Launch of FDA-Approved Hemopatch Pad
Wed 21 May 25, 02:48 PMBreakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
Income before tax | 5628.00M | 10420.00M | 9770.00M | 8997.00M | 1406.00M |
Minority interest | 16.00M | -12.00000M | 13.00M | -3.00000M | -2.00000M |
Net income | 4311.00M | 7910.00M | 7179.00M | 6634.00M | -594.00000M |
Selling general administrative | 745.00M | 36934.00M | 35072.00M | 33061.00M | 21368.00M |
Selling and marketing expenses | - | - | - | - | - |
Gross profit | 54294.00M | 52048.00M | 49046.00M | 45528.00M | 31538.00M |
Reconciled depreciation | 4247.00M | 4512.00M | 4441.00M | 4371.00M | 2718.00M |
Ebit | 16251.00M | 13193.00M | 13911.00M | 11987.00M | 10174.00M |
Ebitda | 20498.00M | 19676.00M | 18558.00M | 16482.00M | 12892.00M |
Depreciation and amortization | 4247.00M | 6483.00M | 4647.00M | 4495.00M | 2718.00M |
Non operating income net other | 169.00M | -270.00000M | -1234.00000M | 45.00M | 4.00M |
Operating income | 16251.00M | 13193.00M | 13911.00M | 11987.00M | 4021.00M |
Other operating expenses | 306385.00M | 277129.00M | 254795.00M | 244789.00M | 184409.00M |
Interest expense | 2287.00M | 2503.00M | 2907.00M | 3035.00M | 2619.00M |
Tax provision | 1463.00M | 2522.00M | 2569.00M | 2366.00M | 2002.00M |
Interest income | 2287.00M | 2503.00M | 2907.00M | 3035.00M | 2619.00M |
Net interest income | -2287.00000M | -2503.00000M | -2907.00000M | -3035.00000M | -2619.00000M |
Extraordinary items | 0.00000M | 0.00000M | -9.00000M | 0.00000M | 100.00M |
Non recurring | 8336.00M | 431.00M | - | - | 6149.00M |
Other items | - | - | - | - | - |
Income tax expense | 1463.00M | 2522.00M | 2569.00M | 2366.00M | 2002.00M |
Total revenue | 322467.00M | 292111.00M | 268706.00M | 256776.00M | 194579.00M |
Total operating expenses | 38212.00M | 37066.00M | 35135.00M | 33541.00M | 21368.00M |
Cost of revenue | 268173.00M | 240063.00M | 219660.00M | 211248.00M | 163041.00M |
Total other income expense net | -10623.00000M | -2773.00000M | -4141.00000M | -2990.00000M | -6145.00000M |
Discontinued operations | - | - | -9.00000M | -9.00000M | -9.00000M |
Net income from continuing ops | 4165.00M | 7898.00M | 7201.00M | 6631.00M | -596.00000M |
Net income applicable to common shares | 4149.00M | 7910.00M | 7179.00M | 6634.00M | -594.00000M |
Preferred stock and other adjustments | - | - | - | - | - |
Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
Total assets | 228275.00M | 232999.00M | 230715.00M | 222449.00M | 196456.00M |
Intangible assets | 24754.00M | 29026.00M | 31142.00M | 33121.00M | 36524.00M |
Earning assets | - | - | - | - | - |
Other current assets | 2685.00M | 5292.00M | 5277.00M | 5113.00M | 4581.00M |
Total liab | 156960.00M | 157618.00M | 161014.00M | 158279.00M | 137913.00M |
Total stockholder equity | 71015.00M | 75075.00M | 69389.00M | 63864.00M | 58225.00M |
Deferred long term liab | 3880.00M | 6270.00M | 6794.00M | 7294.00M | 7677.00M |
Other current liab | 47562.00M | 5604.00M | 5827.00M | 4821.00M | 4876.00M |
Common stock | 48193.00M | 47377.00M | 46513.00M | 45972.00M | 45440.00M |
Capital stock | 48193.00M | 47377.00M | 46513.00M | 45972.00M | 45440.00M |
Retained earnings | 56145.00M | 54906.00M | 49640.00M | 45108.00M | 40911.00M |
Other liab | 19948.00M | 19663.00M | 21033.00M | 21351.00M | 22460.00M |
Good will | 78150.00M | 79121.00M | 79552.00M | 79749.00M | 78678.00M |
Other assets | 7604.00M | 9801.00M | 51046.00M | 9059.00M | 8930.00M |
Cash | 12945.00M | 9408.00M | 7854.00M | 5683.00M | 4059.00M |
Cash and equivalents | 12945.00M | 9408.00M | 7854.00M | 5683.00M | 4059.00M |
Total current liabilities | 69736.00M | 67807.00M | 62017.00M | 53303.00M | 44009.00M |
Current deferred revenue | 3880.00M | 43808.00M | 37974.00M | 32613.00M | 28223.00M |
Net debt | 57787.00M | 66591.00M | 77188.00M | 83319.00M | 69370.00M |
Short term debt | 3456.00M | 5851.00M | 7078.00M | 5377.00M | 1985.00M |
Short long term debt | 1778.00M | 4205.00M | 5440.00M | 3781.00M | 1985.00M |
Short long term debt total | 70732.00M | 75999.00M | 85042.00M | 89002.00M | 73429.00M |
Other stockholder equity | -31858.00000M | -28173.00000M | -28178.00000M | -28235.00000M | -28228.00000M |
Property plant equipment | 12873.00M | 12896.00M | 12606.00M | 32904.00M | 11349.00M |
Total current assets | 65682.00M | 60008.00M | 56369.00M | 50302.00M | 45243.00M |
Long term investments | 21096.00M | 23025.00M | 20812.00M | 17314.00M | 15732.00M |
Net tangible assets | 71015.00M | -33072.00000M | -41305.00000M | -49006.00000M | -56977.00000M |
Short term investments | 2778.00M | 3117.00M | 3000.00M | 2373.00M | 2522.00M |
Net receivables | 27276.00M | 24431.00M | 21742.00M | 19617.00M | 17631.00M |
Long term debt | 50476.00M | 51971.00M | 59207.00M | 64699.00M | 71444.00M |
Inventory | 19090.00M | 17760.00M | 18496.00M | 17516.00M | 16450.00M |
Accounts payable | 14838.00M | 12544.00M | 11138.00M | 10492.00M | 8925.00M |
Total permanent equity | - | - | - | - | - |
Noncontrolling interest in consolidated entity | 300.00M | 306.00M | 312.00M | 306.00M | 318.00M |
Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
Accumulated other comprehensive income | -1465.00000M | 965.00M | 1414.00M | 1019.00M | 102.00M |
Additional paid in capital | - | - | - | - | - |
Common stock total equity | 48193.00M | 47377.00M | 46513.00M | 45972.00M | 45440.00M |
Preferred stock total equity | - | - | - | - | - |
Retained earnings total equity | 56145.00M | 54906.00M | 49640.00M | 45108.00M | 40911.00M |
Treasury stock | -31858.00000M | -28173.00000M | -28178.00000M | -28235.00000M | -28228.00000M |
Accumulated amortization | - | - | - | - | - |
Non currrent assets other | 3968.00M | 4714.00M | 4624.00M | 4600.00M | 5046.00M |
Deferred long term asset charges | - | - | - | - | - |
Non current assets total | 162593.00M | 172991.00M | 174346.00M | 172147.00M | 151213.00M |
Capital lease obligations | 18478.00M | 19823.00M | 20395.00M | 20522.00M | - |
Long term debt total | 50476.00M | 51971.00M | 59207.00M | 64699.00M | 71444.00M |
Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
Investments | -1017.00000M | -2717.00000M | -3172.00000M | -485.00000M | 125.00M |
Change to liabilities | 4260.00M | 5919.00M | 5278.00M | 3550.00M | 2183.00M |
Total cashflows from investing activities | -5047.00000M | -5261.00000M | -5534.00000M | -3339.00000M | -43285.00000M |
Net borrowings | -4211.00000M | -9267.00000M | -5673.00000M | -5320.00000M | 38265.00M |
Total cash from financing activities | -10516.00000M | -11356.00000M | -8155.00000M | -7850.00000M | 36819.00M |
Change to operating activities | 7149.00M | 3018.00M | 2873.00M | 1182.00M | -149.00000M |
Net income | 4165.00M | 7898.00M | 7192.00M | 6631.00M | -596.00000M |
Change in cash | 614.00M | 1648.00M | 2176.00M | 1659.00M | 2395.00M |
Begin period cash flow | 12691.00M | 11043.00M | 5954.00M | 4295.00M | 1900.00M |
End period cash flow | 13305.00M | 12691.00M | 8130.00M | 5954.00M | 4295.00M |
Total cash from operating activities | 16177.00M | 18265.00M | 15865.00M | 12848.00M | 8865.00M |
Issuance of capital stock | - | - | - | - | - |
Depreciation | 4247.00M | 4512.00M | 4441.00M | 4371.00M | 2718.00M |
Other cashflows from investing activities | -1303.00000M | -24.00000M | 75.00M | -397.00000M | -41373.00000M |
Dividends paid | 2907.00M | 2625.00M | 2624.00M | 2603.00M | 2038.00M |
Change to inventory | -1435.00000M | 735.00M | -973.00000M | -1075.00000M | -1153.00000M |
Change to account receivables | -2971.00000M | -2703.00000M | -1510.00000M | -2158.00000M | -1139.00000M |
Sale purchase of stock | -3500.00000M | 549.00M | 257.00M | 185.00M | 688.00M |
Other cashflows from financing activities | -449.00000M | 1523.00M | 10100.00M | 3809.00M | 44935.00M |
Change to netincome | 2533.00M | 549.00M | 1073.00M | 453.00M | 6855.00M |
Capital expenditures | 2727.00M | 2520.00M | 2437.00M | 2457.00M | 2037.00M |
Change receivables | 2971.00M | -2703.00000M | -1510.00000M | 2158.00M | -1139.00000M |
Cash flows other operating | 16177.00M | 1355.00M | 364.00M | 12848.00M | -3.00000M |
Exchange rate changes | - | - | - | - | - |
Cash and cash equivalents changes | 614.00M | 1648.00M | 2176.00M | 1659.00M | 2399.00M |
Change in working capital | 7003.00M | 3948.00M | 3159.00M | 1499.00M | -112.00000M |
Stock based compensation | 447.00M | 484.00M | 400.00M | 453.00M | 280.00M |
Other non cash items | 2390.00M | 1851.00M | 1243.00M | 548.00M | 6488.00M |
Free cash flow | 13450.00M | 15745.00M | 13428.00M | 10391.00M | 6828.00M |
Sector: Healthcare Industry: Healthcare Plans
Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
---|---|---|---|---|---|---|---|---|
CVS CVS Health Corp |
0.45 0.65% | 69.43 | 12.06 | 9.08 | 0.29 | 1.34 | 0.47 | 8.96 |
UNH UnitedHealth Group Incorporated |
9.00 2.88% | 320.97 | 22.57 | 18.38 | 1.33 | 5.65 | 1.38 | 13.97 |
ELV Elevance Health Inc |
6.46 1.66% | 395.42 | 18.00 | 12.66 | 0.65 | 2.87 | 0.74 | |
CI Cigna Corp |
5.65 1.71% | 336.23 | 30.25 | 10.09 | 0.39 | 2.10 | 0.50 | |
HUM Humana Inc |
5.36 2.19% | 249.84 | 19.16 | 14.60 | 0.56 | 3.37 | 0.53 |
CVS Health Corporation provides health services in the United States. It operates through Health Care Benefits, Pharmacy Services, and Retail/LTC segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. The Pharmacy Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, clinical, and disease and medical spend management services. It serves employers, insurance companies, unions, government employee groups, health plans, prescription drug plans, Medicaid managed care plans, plans offered on public health insurance and private health insurance exchanges, other sponsors of health benefit plans, and individuals. This segment operates retail specialty pharmacy stores; and specialty mail-order, mail-order dispensing, and compounding pharmacies, as well as branches for infusion and enteral nutrition services. The Retail/LTC segment sells prescription and over-the-counter drugs, consumer health and beauty products, and personal care products; and provides health care services through its MinuteClinic walk-in medical clinics. This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to care facilities and other care settings. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was incorporated in 1996 and is headquartered in Woonsocket, Rhode Island.
One CVS Drive, Woonsocket, RI, United States, 02895
Name | Title | Year Born |
---|---|---|
Ms. Karen Sue Lynch | Pres, CEO & Director | 1963 |
Mr. Shawn Michael Guertin | Exec. VP & CFO | 1964 |
Dr. Alan M. Lotvin M.D. | Exec. VP & Pres of Pharmacy Services | 1962 |
Mr. James David Clark | Sr. VP, Controller & Chief Accounting Officer | 1965 |
Mr. Tilak Mandadi | Exec. VP & Chief Data, Digital and Technology Officer | 1964 |
Mr. Larry McGrath | Sr. VP of Bus. Devel. & Investor Relations | NA |
Mr. Thomas Michael Moriarty | Exec. VP, Chief Policy & External Affairs Officer and Gen. Counsel | 1964 |
Mr. David A. Falkowski | Exec. VP & Chief Compliance Officer | NA |
Mr. Norman de Greve | Chief Marketing Officer | NA |
Ms. Laurie P. Havanec | Exec. VP & Chief People Officer | 1961 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.